13.64
0.26 (1.94%)
| Penutupan Terdahulu | 13.38 |
| Buka | 13.30 |
| Jumlah Dagangan | 2,159,843 |
| Purata Dagangan (3B) | 3,017,334 |
| Modal Pasaran | 1,940,481,024 |
| Harga / Buku (P/B) | 3.27 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| EPS Cair (TTM) | -3.61 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.49% |
| Nisbah Semasa (MRQ) | 20.35 |
| Aliran Tunai Operasi (OCF TTM) | -319.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -176.84 M |
| Pulangan Atas Aset (ROA TTM) | -39.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Dyne Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.50 |
|
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.56% |
| % Dimiliki oleh Institusi | 110.24% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 38.00 (Chardan Capital, 178.59%) | Beli |
| Median | 30.00 (119.94%) | |
| Rendah | 9.00 (JP Morgan, -34.02%) | Pegang |
| Purata | 26.29 (92.74%) | |
| Jumlah | 6 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 10.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Raymond James | 25 Aug 2025 | 35.00 (156.60%) | Beli | 13.00 |
| 29 Jul 2025 | 31.00 (127.27%) | Beli | 9.20 | |
| Oppenheimer | 06 Aug 2025 | 13.00 (-4.69%) | Beli | 11.59 |
| Stifel | 31 Jul 2025 | 36.00 (163.93%) | Beli | 9.85 |
| Chardan Capital | 29 Jul 2025 | 38.00 (178.59%) | Beli | 9.20 |
| RBC Capital | 29 Jul 2025 | 23.00 (68.62%) | Beli | 9.20 |
| JP Morgan | 15 Jul 2025 | 9.00 (-34.02%) | Pegang | 8.28 |
| Jones Trading | 26 Jun 2025 | 30.00 (119.94%) | Beli | 10.05 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Aug 2025 | Pengumuman | Dyne Therapeutics to Present at Upcoming Investor Conferences |
| 04 Aug 2025 | Pengumuman | Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) |
| 28 Jul 2025 | Pengumuman | Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights |
| 02 Jul 2025 | Pengumuman | Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares |
| 30 Jun 2025 | Pengumuman | Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock |
| 30 Jun 2025 | Pengumuman | Dyne Therapeutics Announces Proposed Public Offering of Common Stock |
| 30 Jun 2025 | Pengumuman | Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |